Patents by Inventor Jeffrey Settleman

Jeffrey Settleman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20230190750
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using MEK antagonists.
    Type: Application
    Filed: June 12, 2015
    Publication date: June 22, 2023
    Applicant: Genentech, Inc.
    Inventors: Richard M. NEVE, Nicholas A. DOMPE, Timothy R. WILSON, Jeffrey SETTLEMAN
  • METHODS OF TREATING AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20170204187
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling and a B-raf antagonist.
    Type: Application
    Filed: June 12, 2015
    Publication date: July 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Richard M. NEVE, Nicholas A. DOMPE, Timothy R. WILSON, Jeffrey SETTLEMAN
  • METHODS OF TREATING CANCER AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20160143910
    Abstract: Provided herein are methods of treating and/or preventing cancer drug resistance using antagonists of KDM5.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 26, 2016
    Applicants: CONSTELLATION PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Shilpi Arora, Michael Robert Costa, Ted Lau, Patrick Trojer, Brian K. Albrecht, Shane Buker, Marie Classon, Victor S. Gehling, Jean-Christophe Harmange, Erica L. Jackson, Jun Liang, Heidi Phillips, Peter Sandy, Jeffrey Settleman, Jean-Philippe Stephan
  • COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
    Publication number: 20150125452
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Timothy R. Wilson, Hartmut Koeppen, Mark Merchant, Jeffrey Settleman
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Publication number: 20080096212
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: August 20, 2007
    Publication date: April 24, 2008
    Applicants: The General Hospital Corporation, Dana Farber Cancer Institute, Inc.
    Inventors: Daphne Bell, Daniel Haber, Pasi Janne, Bruce Johnson, Thomas Lynch, Matthew Meyerson, Juan Paez, William Sellers, Jeffrey Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Publication number: 20060147959
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: December 5, 2005
    Publication date: July 6, 2006
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Bell, Daniel Haber, Pasi Janne, Bruce Johnson, Thomas Lynch, Matthew Meyerson, Juan Paez, William Sellers, Jeffrey Settleman, Raffaella Sordella
  • Gap-related gene, human IQGAP1
    Patent number: 5639651
    Abstract: A purified nucleic acid encoding the IQGAP1 protein, a novel member of the GTPase activating protein family, useful in the diagnosis and treatment of tumors.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: June 17, 1997
    Assignee: The General Hospital Corporation
    Inventors: Lawrence Weissbach, Andre Bernards, Jeffrey Settleman